Bausch Health has patented a packaging system for ophthalmic devices. The system includes a sealed container with unused devices in an aqueous solution containing ectoine, glycosaminoglycan, and crosslinking agents. The solution is sterilized, with an osmolality of at least 150 mOsm/kg and a pH of 6 to 9. GlobalData’s report on Bausch Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Bausch Health Companies Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bausch Health, Cancer treatment biomarkers was a key innovation area identified from patents. Bausch Health's grant share as of May 2024 was 53%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US12012238B2) discloses a novel packaging system for ophthalmic devices. The system includes a sealed container containing unused ophthalmic devices immersed in an aqueous packaging solution. This solution comprises ectoine or an ophthalmologically acceptable ectoine derivative, along with a modified glycosaminoglycan. The aqueous solution meets specific criteria, including an osmolality of at least 150 mOsm/kg and a pH range of 6 to 9. The modified glycosaminoglycan is a reaction product of different glycosaminoglycans and crosslinking agents, providing a unique composition for preserving ophthalmic devices.

Furthermore, the patent details variations in the packaging system, such as the use of specific glycosaminoglycans like hyaluronic acid and chondroitin sulfate, as well as different ectoine derivatives like L-ectoine and hydroxyectoine. The aqueous packaging solution contains precise concentrations of ectoine or its derivatives and the modified glycosaminoglycan to ensure stability and efficacy. Additionally, the modified glycosaminoglycan can be further enhanced with glycophospholipid polymers or grafted glycosaminoglycan polymers, providing versatility in the packaging system. Overall, the patent highlights a comprehensive approach to packaging ophthalmic devices, focusing on maintaining their integrity and functionality through innovative formulations and compositions.

To know more about GlobalData’s detailed insights on Bausch Health, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies